Stem cell transplantation for lymphoma

[1]  Scott E. Smith,et al.  Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial , 2021, Blood.

[2]  C. Turtle,et al.  Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. , 2021, Blood.

[3]  M. Mohty,et al.  Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies , 2021, Blood Cancer Journal.

[4]  K. Meehan,et al.  Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma? , 2021, JAMA oncology.

[5]  Matthew J. Frigault,et al.  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma , 2021, Leukemia.

[6]  K. Ahn,et al.  Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era? , 2020, Blood.

[7]  Ash A. Alizadeh,et al.  Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. , 2020, Blood advances.

[8]  S. Fujiwara,et al.  Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study , 2020, International Journal of Hematology.

[9]  M. Kersten,et al.  Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study , 2020, Haematologica.

[10]  M. Shipp,et al.  Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087. , 2019, Blood.

[11]  R. Suzuki,et al.  High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  C. Martínez,et al.  Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  N. Russell,et al.  Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma , 2018, British journal of haematology.

[14]  S. Montoto,et al.  Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR , 2018, Cancer.

[15]  P. Hari,et al.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. , 2017, Blood.

[16]  R. Houot,et al.  Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.

[17]  R. Houot,et al.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.

[18]  A. Nademanee,et al.  Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Alan M. Miller,et al.  Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  A. Zelenetz,et al.  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. , 2015, Blood.

[21]  E. Kimby,et al.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma , 2014, Leukemia.

[22]  D. Niederwieser,et al.  Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.